Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-06-04
2011-12-27
Murray, Jeffrey (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08084462
ABSTRACT:
The present invention relates to the pharmaceutical compositions incorporating compounds capable of affecting nicotinic acetylcholinergic receptors (nAChRs), for example, as modulators of specific nicotinic receptor subtypes (specifically, the α7 nAChR subtype). The present invention also relates to methods for treating a wide variety of conditions and disorders, particularly those associated with dysfunction of the central and autonomic nervous systems.
REFERENCES:
patent: 4203990 (1980-05-01), Yen
patent: 4970315 (1990-11-01), Schmidhalter
patent: 5212188 (1993-05-01), Caldwell et al.
patent: 5217975 (1993-06-01), Wadsworth et al.
patent: 5219849 (1993-06-01), Lotti et al.
patent: 5276043 (1994-01-01), Lippiello et al.
patent: 5346906 (1994-09-01), Baker et al.
patent: 5510355 (1996-04-01), Bencherif et al.
patent: 5583140 (1996-12-01), Bencherif et al.
patent: 5597919 (1997-01-01), Dull et al.
patent: 5604231 (1997-02-01), Smith et al.
patent: 5616707 (1997-04-01), Crooks et al.
patent: 5616716 (1997-04-01), Dull et al.
patent: 5663356 (1997-09-01), Ruecroft et al.
patent: 5811442 (1998-09-01), Bencherif et al.
patent: 5824692 (1998-10-01), Lippiello et al.
patent: 5852041 (1998-12-01), Cosford et al.
patent: 5859004 (1999-01-01), Olesen
patent: 5861423 (1999-01-01), Caldwell et al.
patent: 5952339 (1999-09-01), Bencherif et al.
patent: 6953855 (2005-10-01), Mazurov et al.
patent: 7425561 (2008-09-01), Mazurov et al.
patent: 2009/0048290 (2009-02-01), Dull et al.
patent: 173570 (1996-04-01), None
patent: WO 91/12254 (1991-08-01), None
patent: WO 94/08992 (1994-04-01), None
patent: WO 95/03306 (1995-02-01), None
patent: WO 96/12711 (1996-05-01), None
patent: WO 97/01556 (1997-01-01), None
patent: WO 97/11072 (1997-03-01), None
patent: WO 98/25619 (1998-06-01), None
patent: WO 98/54181 (1998-12-01), None
patent: WO 99/00385 (1999-01-01), None
patent: WO 99/51602 (1999-10-01), None
patent: WO 00/34276 (2000-06-01), None
patent: WO 01/85727 (2001-11-01), None
http://www.schizophrenia.com/diag.php, last accessed Feb. 2, 2011.
Decker et al.,The Potential of Neuronal Nicotinic Acetylcholine Receptor Agonists for Treating CNS Conditions, Expert Opinion on Drug Discovery Sep. 2008, vol. 3, No. 9, pp. 1027-1040.
http://schizophrenia.com/diag.php; last accessed on Nov. 9, 2009.
Van Dijk, Jeanette P.M. et al., “Nicotine inhibits cytokine synthesis by mouse colonic mucosa.”European Journal of Pharmacology, 278, R11-R12 (1995).
Hanisch, Uwe-Karsten et al., “Modulation of Hippocampal Acetylcholine Release: A Potent Central Action of Interleukin-2,”The Journal of Neuroscience, vol. 13(8), pp. 3368-3374 (1993).
Madretsma, Stanley et al., “In-vivo effect of nicotine on cytokine production by human non-adherent mononuclear cells,”European Journal of Gastroenterology&Hepatology, vol. 8, No. 10, pp. 1017-1020 (1996).
Madretsma, G.S., et al. “Nicotine inhibits the in vitro production of interleukin 2 and tumour necrosis factor-α by human mononuclear cells,”Immunopharmacology, 35 pp. 47-51(1996).
Peacock, Mark E., et al., “The Effect of Nicotine on Reproduction and Attachment of Human Gingival Fibroblasts In Vitro,”J. Periodontal, vol. 64, No. 7, pp. 658-665 (1993).
Sandborn, W.J. et al., “Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study,”Ailment Pharmacol. Ther., 11, pp. 663-671 (1997).
Zijlstra, F. J. et al., “Effect of nicotine on rectal mucus and mucosal eicosanoids,”Gut, 35, pp. 247-251 (1994).
Pullan, Rupert D., “Colonic mucus, smoking and ulcerative colitis,”Ann R. Coll. Surg Engl., 78, pp. 85-91 (1996).
Pullan, Robert D. et al., “Transdermal Nicotine for Active Ulcerative Colitis,”The New England Journal of Medicine, vol. 330, No. 12, pp. 811-815 (1994).
Silverstein, Marc D., M.D. et al., “Cigarette Smoking and Ulcerative Colitis: A Case-Control Study,” Mayo Clinic Proc., vol. 69 pp. 425-429 (1994).
Birtwistle, Jon,Postgrad Med. J., “The role of cigarettes and nicotine in the onset and treatment of ulcerative colitis,” vol. 72, pp. 714-718 (1996).
Ebadi, M. et al., “Neurotrophins and Their Receptors in Nerve Injury and Repair,”Neurochem Int., vol. 30, Nos. 4/5, pp. 347-374 (1997).
Matthys, Patrick, Ph.D., et al., “Cytokines and Cachexia,”Nutrition, vol. 13, No. 9, pp. 763-770 (1997).
Jonakait, G. Miller, TINS, “Neural-immune interactions in sympathetic ganglia,” vol. 16, No. 10, pp. 419-423 (1993).
Wallace, John L., et al., “Inflammatory Mediators in Gastrointestinal Defense and Injury,”Proc. Soc. Exp. Biol. Med., vol. 214, pp. 192-203 (1997).
Barnes, Peter J., Int. “Nuclear Factor-κB,”J. Biochem. Cell Biol., vol. 29, No. 6, pp. 867-870 (1997).
Sartor, R. Balfour M.D., “Pathogenesis and Immune Mechanisms of Chronic Inflammatory Bowel Diseases,”The American Journal of Gastroenterology, vol. 92, No. 12, pp. 5S-11S (1997).
CAS Printout for IN 173 570, Jun. 4, 1994.
CAS Printout for Schmidhalter et al., Nov. 1990.
CAS Printout for Begue et al., Dec. 1969.
Holladay, M. W. et al.J. Med. Chem., vol. 40, No. 26, pp. 4169-4194 (1997).
Olesen, P.H. et al.,Bioorganic&Medicinal Chemistry Letters, vol. 7, No. 15, pp. 1963-1968 (1997).
Yanina et al.,Khim.-Karm, vol. 21(7), pp. 808-811 (1987).
International Search Report, PCT/US99/19906, Jan. 13, 2000.
Heeschen, Christoper, et al., “A Novel Angiogenic Pathway Mediated by Non-Neuronal Nicotinic Acetylcholine Receptors,”The Journal of Clinical Investigation, vol. 110, No. 4, pp. 527-536 (Aug. 2002).
Tracey, Kevin J., “The Inflammatory Reflex,”Nature, vol. 420, pp. 853-859 (Dec. 2002).
Wang, Hong, et al, “Nicotinic Acetylcholine Receptor α7 subunit is an Essential Regulator of Inflammation,”Nature, advance online publication, Dec. 22, 2002, pp. 1-4.
Evans, et al., Isotopic labeling with carbon-14 and tritium,Principles of Radiopharmacology, 1992, p. 11-13.
International Search Report (PCT/US2004/005044, dated Nov. 3, 2004).
http://en.wikipedia.org/wiki/Attention—deficit—disorder, last accessed on Jul. 22, 2010.
http://www.medicinenet.com/learning—disability/article.htm, last accessed on Jul. 22, 2010.
http://www.mentalhealth.org.uk/information/mental-health-a-z/dementia/, last accessed, Jul. 14, 2010.
Maskell, et. al., “Inhibition of human α7 nicotinic acetylcholine receptors by opn channel blockers of N-methyl-D-asparate receptors,”British Journal of Pharmacology, 140(7): 1313-1319 (2003).
Boess, et. al., “The novel α7 Nicotinic Acetylcholine Receptor Agonist N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide Improves Working and Recognition Memory in Rodents,”The Journal of Pharmacology and Experimental Therapeutics, 321(2): 716-725 (2007).
Tcheremissine, et. al., “Pharmacotherapy of adult attention deficit/hyperactivity disorder: review of evidence-based practices and future directions,”Expert Opin. Pharmacotherapy, 1299-1310 (2008) 9(8).
Leiser, Steven C. et al., “A cog in cognition: How the α7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits,”Pharmacology&Therapeutics, 122: 302-311 (2009).
Young, Jared W. et al., “Nicotine Improves Sustained Attention in Mice: Evidence for Involvement of the α7 Nicotinic Acetylcholine Receptor,”Neuropsychopharmacology, 29: 891-900 (2004).
Dorwald, F.Z.,Side Reactions in Organic Synthesis; A Guide to Successful Syntheses Design, p. IX of Preface (2006).
Klucik Jozef
Mazurov Anatoly A.
Miao Lan
Miller Craig Harrison
Phillips Teresa Youngpeter
Fix Amy H.
Murray Jeffrey
Targacept, Inc.
LandOfFree
3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4265749